• 

  05.23.13

  Clinical trial tests targeting prostate cancer treatment

  Study to evaluate whether drug works better against tumors with specific genetic anomaly.

  A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for prostate cancer. The trial, led by investigators at the University of Michigan Comprehensive Cancer Center, is being conducted at 11 sites throughout the country.
• 

  05.21.13

  Commonly used catheters double risk of blood clots in ICU and cancer patients

  U-M study finds peripherally inserted central catheters - an often preferred route for delivery of IV medications - increase risk of blood clots in sickest patients.

  Touted for safety, ease and patient convenience, peripherally inserted central catheters have become many clinicians' go-to for IV delivery of antibiotics, nutrition, chemotherapy, and other medications.

  But compared to other central venous catheters (CVCs), these commonly-used catheters (known as PICCs) more than double the risk of dangerous blood clots - especially among patients who are critically ill or who have cancer.
• 

  05.17.13

  Decoded: Molecular messages that tell prostate and breast cancers to spread

  Cancer cells are wily, well-traveled adversaries, constantly side-stepping treatments to stop their spread.

  But for the first time, scientists at the University of Michigan have decoded the molecular chatter that ramps certain cancer cells into overdrive and can cause tumors to metastasize throughout the body.

  Español        |        Português

More 2013 releases